Phosphodiesterases Regulate BAY 41-2272-Induced VASP Phosphorylation in Vascular Smooth Muscle Cells

Area of Science:

• Pharmacology
• Cell Biology
• Biochemistry

Background:

• Soluble guanylyl cyclase (sGC) stimulators, like BAY 41-2272 (BAY), influence cyclic nucleotide levels and vascular smooth muscle cell (VSMC) proliferation.
• Vasodilator-stimulated phosphoprotein (VASP) is a key regulator of the actin cytoskeleton and cell motility.
• Phosphodiesterases (PDEs) modulate intracellular cyclic nucleotide concentrations.

Purpose of the Study:

• To elucidate the mechanisms by which BAY 41-2272 regulates VASP phosphorylation in VSMCs.
• To investigate the role of different phosphodiesterase (PDE) isoforms in mediating BAY 41-2272's effects on VASP phosphorylation.

Main Methods:

• Treatment of VSMCs with BAY 41-2272, cyclic nucleotide analogs (8Br-cGMP, 8Br-cAMP), and selective PDE inhibitors (PDE3, PDE4, PDE5).
• Assessment of VASP phosphorylation at Ser239 (PKG-dependent) and Ser157 (PKA-dependent) sites using Western blotting or similar techniques.
• Comparison of BAY 41-2272's effects with direct cyclic nucleotide stimulation.

Main Results:

• BAY 41-2272 alone increased VASP phosphorylation at Ser239 and Ser157, indicating activation of both PKG and PKA signaling.
• Non-selective PDE inhibition (IBMX) affected only VASP(Ser157) phosphorylation, while selective PDE3 or PDE4 inhibition attenuated phosphorylation at both sites.
• PDE5 inhibition potentiated BAY-mediated VASP(Ser157) phosphorylation, but not VASP(Ser239).
• Direct cyclic nucleotide analogs showed differential responses to PDE inhibition compared to BAY 41-2272.
• BAY 41-2272's mechanism involves cAMP and cGMP, modulated by PDEs, differing from direct cyclic nucleotide analogs in VASP phosphorylation.

Conclusions:

• BAY 41-2272 regulates VASP phosphorylation in VSMCs via both cAMP and cGMP pathways, with significant involvement of PDE3, PDE4, and PDE5.
• The mechanism of action of BAY 41-2272 on VASP phosphorylation is distinct from that of direct cyclic nucleotide analogs.
• These findings support BAY 41-2272's role in regulating VSMC growth and suggest its potential as a therapeutic agent for vasculoproliferative disorders.